Nurix Therapeutics (NRIX) Stock: Slides as Losses Widen Despite Pipeline Progress

TLDR

• NRIX dips 1.65% as losses widen despite pipeline progress

• Revenue drops sharply as Sanofi collaboration contributions decline

• R&D spending rises on accelerated clinical trial expansion

• Bexobrutideg advances toward Phase 3 and approval pathway

• Strategic partnerships support long-term pipeline growth

Nurix Therapeutics (NRIX) shares fell to $16.08, down 1.65%, reflecting weak sentiment despite ongoing clinical progress. The stock showed a steady intraday decline with brief rebounds that failed to hold. The company reported higher losses alongside advancing its oncology and immunology pipeline.

Nurix Therapeutics, Inc., NRIX

Financial Results Show Rising Costs and Wider Losses

Nurix reported quarterly revenue of $6.3 million, down sharply from $18.5 million a year earlier. The decline followed reduced contributions from its Sanofi collaboration after initial research phases ended. As a result, top-line pressure weighed on overall financial performance.

Research and development expenses rose to $84.1 million from $69.7 million in the prior year period. The increase reflected higher clinical activity, staffing costs, and manufacturing efforts tied to pipeline expansion. The company accelerated enrollment in key trials to support upcoming regulatory milestones.

Net loss widened to $87.2 million compared with $56.4 million in the same quarter last year. Loss per share also increased to $0.79, highlighting rising operating expenses. Despite this, Nurix maintained a strong cash position of $540.7 million to support ongoing programs.

Bexobrutideg Program Advances Toward Late-Stage Development

Nurix continues to progress bexobrutideg, its lead BTK degrader targeting B-cell malignancies and autoimmune diseases. The Phase 2 DAYBreak CLL-201 study remains active and targets patients with limited treatment options. This trial aims to support a potential accelerated approval pathway.

The company plans to launch a global Phase 3 confirmatory trial by mid-2026. This study will compare bexobrutideg with pirtobrutinib in relapsed or refractory chronic lymphocytic leukemia patients. The program moves closer to full regulatory approval.

In parallel, Nurix runs additional studies to expand the drug’s potential use cases. These include early-stage trials and healthy volunteer studies assessing safety and pharmacological effects. Therefore, the company continues to build a broad clinical foundation for future indications.

Pipeline Expansion and Strategic Collaborations Support Growth

Beyond bexobrutideg, Nurix advances several pipeline candidates across oncology and immunology. Zelebrudomide remains in Phase 1 trials targeting B-cell malignancies, including lymphoma indications. NX-1607 progresses in early-stage trials for solid tumors and immune-related cancers.

The company also strengthens its position through collaborations with major pharmaceutical partners. Sanofi continues work on a STAT6 degrader, while Gilead advances an IRAK4 program in early human studies. These partnerships provide shared development opportunities and potential milestone payments.

Nurix retains opt-in rights to co-develop and share in profits for key programs. This structure allows the company to expand participation after clinical validation. As a result, its pipeline strategy combines internal development with external collaboration to drive long-term growth.